Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +116.67% | +41.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +102.50% | +30.55% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.06% | +0.33% | +0.31% | +0.36% | -17.05% |
| Weighted Average Shares Diluted Growth | +9.06% | +0.33% | +0.31% | +0.36% | -17.05% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -36.79% | -42.83% | -48.76% | -51.95% | -19.49% |
| Book Value per Share Growth | -49.16% | -51.20% | -58.52% | -62.72% | -37.05% |
| Debt Growth | +6.73% | +1.59% | -1.58% | -1.55% | -1.31% |
| R&D Expense Growth | +4.25% | +5.13% | -12.62% | -26.31% | -43.10% |
| SG&A Expenses Growth | -7.52% | -16.50% | -16.26% | -39.58% | -26.29% |